Site Editor
Joyce F. Liu, MD, MPH
Joyce F. Liu, MD, MPH
Posted: Thursday, January 8, 2026
Final overall survival data from the phase III DUO-O/ENGOT-ov46/GOG-3025 trial offer an updated perspective on a previously reported progression-free survival benefit in patients with newly diagnosed, non–tumor BRCA–mutated (non-tBRCAm) advanced ovarian cancer. The findings were presented by Carol Aghajanian, MD, during the European Society for Medical Oncology (ESMO) Congress 2025 (Abstract LBA44). Earlier analyses demonstrated statistically significant progression-free survival improvements with the addition of durvalumab and olaparib to standard paclitaxel/carboplatin plus bevacizumab.
The study enrolled 1,130 patients with non-tBRCAm advanced ovarian cancer who were randomly assigned after one cycle of chemotherapy to receive paclitaxel/carboplatin plus bevacizumab followed by bevacizumab alone (Arm 1, n = 378); the same regimen plus durvalumab (Arm 2, n = 374); or the Arm 2 regimen with the addition of olaparib (Arm 3, n = 378). Median follow-up was approximately 56 months.
In the intent-to-treat population, final overall survival did not differ significantly between Arm 3 and the control arm (hazard ratio [HR] = 0.92; P = .378), nor between Arm 2 and the control (HR = 0.97; P = .785). However, updated progression-free survival results remained consistent with the previously observed benefit.
Among homologous recombination deficiency (HRD)-positive patients, overall survival showed a numerical trend favoring Arm 3 (HR = 0.80), though this was not statistically significant. Patients in this subgroup experienced a median progression-free survival of 45.1 months, with 47% remaining progression-free at 48 months, underscoring the durability of response in HRD-positive disease. In HRD-negative patients, overall survival and progression-free survival outcomes aligned with earlier analyses and showed no meaningful deviation from prior results.
Safety across all arms was consistent with known profiles of bevacizumab, durvalumab, and olaparib, and no new safety signals emerged.
Disclosure: For full disclosures of all study authors, visit cslide.ctimeetingtech.com.
JNCCN Spotlights
